Nerea Zabaleta

Massachusetts Eye and Ear Infirmary — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

13h-index994citations41works4.42yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(23), CRISPR and Genetic Engineering(12), SARS-CoV-2 and COVID-19 Research(9), Animal Virus Infections Studies(8), RNA Interference and Gene Delivery(6)

Publications40 total

13OIdentifying naturally occurring adeno-associated virus serotypes that transduce mouse skeletal muscles fibro-adipogenic progenitors in vivo
Neuromuscular Disorders·2025
E2A, VA RNA I, and L4-22k adenoviral helper genes are sufficient for AAV production in HEK293 cells
Molecular Therapy — Methods & Clinical Development·2024· 5 citedOpen Access
Boost and Increased Antibody Breadth Following a Second Dose of PARVAX for SARS-CoV-2 in Mice and Nonhuman Primates
Vaccines·2024Open Access
Gene editing in liver diseases
FEBS Letters·2024· 6 citedOpen Access
FRI-152-YI Gene editing to treat liver metabolic disorders: harnessing paired Cas9-Nickases for efficient and safe treatment of primary hyperoxaluria type 1
Journal of Hepatology·2024
Efficient and safe therapeutic use of paired Cas9-nickases for primary hyperoxaluria type 1
EMBO Molecular Medicine·2024· 20 citedOpen Access
Tracing the fate of AAV vectors in the body
Nature Biotechnology·2023· 5 cited
Correlating physicochemical and biological properties to define critical quality attributes of a rAAV vaccine candidate
Molecular Therapy — Methods & Clinical Development·2023· 10 citedOpen Access
Correlating physicochemical and biological properties to define critical quality attributes of a recombinant AAV vaccine candidate (Dataset)
2023
Correlating physicochemical and biological properties to define critical quality attributes of a recombinant AAV vaccine candidate
2023Open Access
Efficient in vivo genome editing prevents hypertrophic cardiomyopathy in mice
Nature Medicine·2023· 173 citedOpen Access
Gene therapy for liver diseases — progress and challenges
Nature Reviews Gastroenterology & Hepatology·2023· 59 cited
Ancestral library identifies conserved reprogrammable liver motif on AAV capsid
Cell Reports Medicine·2022· 23 citedOpen Access
Review 2: "Accelerated Waning of the Humoral Response to SARS-CoV-2 Vaccines in Obesity"
2022Open Access
Reviews of "Accelerated Waning of the Humoral Response to SARS-CoV-2 Vaccines in Obesity"
2022Open Access
Durable immunogenicity, adaptation to emerging variants, and low-dose efficacy of an AAV-based COVID-19 vaccine platform in macaques
Molecular Therapy·2022· 13 citedOpen Access
Immunogenicity of an AAV-Based COVID-19 Vaccine in Murine Models of Obesity and Aging
Viruses·2022· 5 citedOpen Access
Computed tomography and [18F]-FDG PET imaging provide additional readouts for COVID-19 pathogenesis and therapies evaluation in non-human primates
iScience·2022· 11 citedOpen Access
mRNA and gene editing: Late breaking therapies in liver diseases
Hepatology·2022· 34 citedOpen Access
An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates
Cell Host & Microbe·2021· 80 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Gloria González‐Aseguinolaza(20), Luk H. Vandenberghe(17), Reynette Estelien(10), Urja Bhatt(9), Julio Sanmiguel(9), Cheikh Tacko Diop(9), Laura Torella(7), David Salas(7), Dawid Maciorowski(5), Eric Zinn(4), Wenlong Dai(4), Cécile Hérate(4), Roger Le Grand(4), Anna Majowicz(4), Estefanía Rodríguez‐García(4), Harald Petry(4), Valérie Ferreira(4), Nicholas D. Weber(3), África Vales(3), Cristina Olagüe(3)